VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome‐negative B‐precursor acute lymphoblastic leukaemia in first relapse

Adults with relapsed or refractory B‐precursor acute lymphoblastic leukaemia (R/R BCP‐ALL) have very poor outcome. Blinatumomab as single agent has shown activity in R/R BCP‐ALL. We aimed to assess the activity of blinatumomab in concomitant association with intensive chemotherapy. Seventeen patient...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2022-08, Vol.198 (3), p.523-527
Main Authors: Heraudet, Luc, Galtier, Jean, Favre, Simon, Peyraud, Florent, Cazaubiel, Titouan, Leroy, Harmony, Mottal, Nathan, Gros, François‐Xavier, Forcade, Edouard, Clément, Laurence, Dumas, Pierre‐Yves, Pigneux, Arnaud, Leguay, Thibaut
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Asparaginase
Chemotherapy
Cytarabine
Dexamethasone
Etoposide
Hematology
Human health and pathology
Life Sciences
Mitoxantrone
Philadelphia chromosome
Remission
Stem cell transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adults with relapsed or refractory B‐precursor acute lymphoblastic leukaemia (R/R BCP‐ALL) have very poor outcome. Blinatumomab as single agent has shown activity in R/R BCP‐ALL. We aimed to assess the activity of blinatumomab in concomitant association with intensive chemotherapy. Seventeen patients with R/R BCP‐ALL were treated with combination of blinatumomab and VANDA (etoposide, cytarabine, mitoxantrone, dexamethasone and asparaginase) regimen. Complete remission (CR) was achieved in 14/17 patient (82%) and 11/17 (65%) were transplanted. One‐year leukaemia‐free survival was 58.8% for the whole cohort and 90.9% for transplanted patients. These preliminary data suggest that the VANDA‐blinatumomab salvage regimen leads to a very high rate of CR and HSCT in suitable patients.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.18218